"Foreign Investors Snap Up Kolon TissueGene, Target Price Doubles... Pan Ocean Sees Strong LNG Growth [Zootopia]"

[Financial News] Here is a summary of major securities firm reports for the morning of November 28.
Pan Ocean is expected to see a clearer increase in operating profit next year as it expands its LNG carrier fleet. Kolon TissueGene is experiencing a revaluation of TG-C's value due to large-scale net purchases by overseas investors. NEOWIZ continues to show improved performance, driven by the success of new releases and the expansion of existing IP.
◆Pan Ocean (028670)― iM Securities / Researcher Bae Se-ho
- Target price: Not provided
- Investment opinion: Not provided
iM Securities noted that Pan Ocean is rapidly increasing its LNG carrier fleet, stabilizing its profit structure and raising the likelihood of higher operating profit next year. According to researcher Bae Se-ho, Pan Ocean is expected to have 14 LNG carriers by the end of 2025, all of which are under long-term contracts, ensuring stable earnings. As a result, Pan Ocean’s LNG segment operating profit is projected to reach 185 billion KRW, up 22.2% year-on-year.
◆Kolon TissueGene (950160)― Korea Investment & Securities / Researcher Wi Hae-joo
- Target price: 150,000 KRW (raised from 100,000 KRW)
- Investment opinion: Buy
Korea Investment & Securities reported that foreign investors are continuing to buy shares, highly valuing the clinical and commercialization potential of TG-C. Researcher Wi Hae-joo noted that cumulative net foreign purchases in November have reached 850,000 shares, with foreign investors leading the positive assessment of TG-C’s clinical and commercial prospects. Furthermore, Eli Lilly is expected to announce the results of its phase 3 clinical trial for an obesity-related knee osteoarthritis treatment by year-end. If the results are positive, global interest in TG-C, a fundamental osteoarthritis treatment candidate, is also expected to rise.※TG-CTG-C is a cell and gene therapy aimed at regenerating damaged knee cartilage and is Kolon TissueGene’s core pipeline. Targeting patients suffering from pain due to cartilage wear from degenerative osteoarthritis, the therapy seeks to restore damaged cartilage tissue using stem cells and growth factors.
◆NEOWIZ (095660)― Shinhan Securities / Senior Researcher Kang Seok-oh
- Target price: 34,000 KRW (raised from 30,000 KRW)
- Investment opinion: Buy
Shinhan Securities expects NEOWIZ’s share price to continue its stable upward trend, driven by the performance of new and existing hit titles. Researcher Kang Seok-oh noted that third-quarter operating profit exceeded market expectations, and the previously underperforming ‘BrownDust2’ has now become a major intellectual property, contributing to earnings surprises. Kang also explained that NEOWIZ’s new title ‘Shape of Dreams’ sold 500,000 copies within two weeks of launch, boosting results, while the globally recognized ‘Lies of P’ has laid the groundwork for future series expansion.

sms@fnnews.com Reporter Seong Min-seo Reporter